Hospital
Holy Name Medical Center INC.
Holy Name Medical Center INC. was paid $107.07M by Medicaid between Jan 2018 and Nov 2024, across 411 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoHOLY NAME MEDICAL CENTER INC.
TEANECK, NJ 07666
TEANECK, NJ 07666
33aNPI1104859131assigned 07/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$107.07M
24GClaims1,876,332
24DCodes billed411
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#18 of 93
Median peer was paid$30.60M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 253,750 | $15.77M | |
| 2019 | 270,935 | $16.53M | |
| 2020 | 205,888 | $12.48M | |
| 2021 | 288,333 | $17.91M | |
| 2022 | 317,299 | $16.66M | |
| 2023 | 324,262 | $16.24M | |
| 2024incomplete | 215,865 | $11.48M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 43,793 | 39,980 | $12.86M |
| J2350 | Injection, ocrelizumab, 1 mg | 8.5% | 550 | 437 | $9.11M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.0% | 21,740 | 20,427 | $6.39M |
| J2323 | Injection, natalizumab, 1 mg | 5.4% | 1,318 | 1,158 | $5.83M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 90,089 | 20,266 | $3.92M |
| G0378 | Hospital observation service, per hour | 3.4% | 8,752 | 7,448 | $3.64M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 17,906 | 16,081 | $3.43M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.8% | 7,966 | 7,439 | $3.04M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.4% | 3,345 | 3,211 | $2.59M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.1% | 9,710 | 6,331 | $2.21M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.1% | 57,771 | 14,184 | $2.20M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.8% | 1,590 | 1,518 | $1.88M |
399 more codes
| 76641 | 1.6% | 12,287 | $1.72M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 8,240 | $1.55M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 14,428 | $1.54M |
| 93458 | 1.4% | 1,449 | $1.49M | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 13,612 | $1.43M |
| 93017 | 1.3% | 6,242 | $1.37M | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 1.2% | 4,837 | $1.24M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 4,363 | $1.13M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.0% | 21,452 | $1.08M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,217 | $1.02M |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 7,134 | $955K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 920 | $947K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 7,158 | $824K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 16,583 | $808K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 14,451 | $732K |
| 80053 | Comprehensive metabolic panel | <1% | 79,511 | $690K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 28,613 | $682K |
| J0897 | Injection, denosumab, 1 mg | <1% | 889 | $663K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,851 | $660K |
| 93970 | <1% | 2,612 | $658K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 8,542 | $657K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,827 | $649K |
| 96417 | <1% | 2,773 | $643K | |
| 19083 | <1% | 816 | $613K | |
| 96415 | <1% | 3,100 | $610K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 77,313 | $587K |
| OP272 | <1% | 39,997 | $552K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,589 | $543K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,239 | $532K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 15,716 | $518K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 184 | $475K |
| 76813 | <1% | 3,038 | $460K | |
| 76830 | Ultrasound, transvaginal | <1% | 4,000 | $451K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 10,677 | $439K |
| 76801 | <1% | 4,825 | $435K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,468 | $429K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,033 | $426K |
| OP259 | <1% | 66,487 | $413K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 602 | $392K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,609 | $379K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,511 | $373K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 35,139 | $363K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,234 | $360K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 11,930 | $355K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 11,340 | $334K |
| 77066 | Tomosynthesis, mammo | <1% | 2,714 | $333K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13,364 | $324K |
| 77080 | <1% | 3,907 | $322K | |
| 77065 | Tomosynthesis, mammo | <1% | 3,559 | $310K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,494 | $304K |
| 94060 | <1% | 2,258 | $304K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 94,893 | $289K |
| 71250 | <1% | 2,753 | $289K | |
| 93971 | <1% | 1,866 | $278K | |
| 0001A | <1% | 9,051 | $264K | |
| 58558 | <1% | 271 | $256K | |
| 97010 | <1% | 26,799 | $252K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,069 | $251K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,651 | $243K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,181 | $242K |
| 97014 | <1% | 11,981 | $238K | |
| 76642 | <1% | 2,314 | $236K | |
| 0002A | <1% | 7,508 | $234K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,143 | $233K |
| 76536 | <1% | 2,059 | $231K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,684 | $227K |
| 97161 | <1% | 5,496 | $226K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 6,434 | $226K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,659 | $222K |
| 59025 | Fetal non-stress test | <1% | 1,283 | $214K |
| 96376 | <1% | 4,463 | $207K | |
| 93880 | <1% | 1,367 | $207K | |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | <1% | 102 | $199K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,531 | $193K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 68 | $193K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 337 | $185K |
| 76775 | <1% | 2,049 | $165K | |
| 97162 | <1% | 3,797 | $160K | |
| 96367 | <1% | 2,996 | $148K | |
| 47562 | <1% | 121 | $148K | |
| 76820 | <1% | 1,163 | $147K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,007 | $145K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,426 | $143K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 765 | $137K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 466 | $135K |
| 71045 | Radiologic examination, chest; single view | <1% | 16,580 | $132K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,092 | $128K |
| 72197 | <1% | 264 | $126K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 2,125 | $118K |
| 77336 | <1% | 1,437 | $117K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,876 | $117K |
| 82962 | <1% | 25,876 | $110K | |
| 80061 | Lipid panel | <1% | 16,366 | $110K |
| C1769 | Guide wire | <1% | 5,075 | $106K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,349 | $105K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 8,956 | $103K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,435 | $101K |
| J9312 | Injection, rituximab, 10 mg | <1% | 19 | $99K |
| 96523 | <1% | 1,935 | $99K | |
| 86900 | <1% | 9,019 | $99K | |
| 74183 | <1% | 267 | $93K | |
| 95811 | <1% | 71 | $91K | |
| 82378 | <1% | 6,287 | $86K | |
| 86850 | <1% | 12,131 | $86K | |
| 74178 | <1% | 248 | $85K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 3,490 | $85K |
| 78999 | <1% | 1,477 | $83K | |
| 93976 | <1% | 886 | $81K | |
| 0223U | <1% | 1,122 | $80K | |
| 85027 | <1% | 22,042 | $79K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,742 | $77K |
| 93270 | <1% | 3,042 | $76K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,158 | $76K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 932 | $75K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 528 | $75K |
| 72100 | <1% | 2,919 | $73K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,414 | $72K |
| 97165 | <1% | 1,649 | $71K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,361 | $71K |
| 94729 | <1% | 1,486 | $69K | |
| 97116 | <1% | 4,832 | $69K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,638 | $68K |
| 82728 | <1% | 8,180 | $66K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,624 | $65K |
| 77334 | <1% | 314 | $65K | |
| 88342 | <1% | 4,747 | $62K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,458 | $62K |
| 84484 | <1% | 17,654 | $61K | |
| 73560 | <1% | 2,351 | $60K | |
| 96411 | <1% | 383 | $59K | |
| 83880 | <1% | 7,033 | $57K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 21,176 | $57K |
| 93798 | <1% | 1,276 | $56K | |
| 85610 | <1% | 23,696 | $56K | |
| 82607 | <1% | 5,944 | $56K | |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | <1% | 131 | $56K |
| 73130 | <1% | 2,017 | $55K | |
| 73610 | <1% | 2,309 | $54K | |
| 83735 | <1% | 18,392 | $54K | |
| 73630 | <1% | 2,399 | $54K | |
| J9310 | Injection, rituximab, 100 mg | <1% | 18 | $53K |
| 93923 | <1% | 349 | $51K | |
| 96402 | <1% | 1,031 | $51K | |
| 81001 | <1% | 21,838 | $49K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,887 | $49K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,832 | $49K |
| 73030 | <1% | 2,531 | $48K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,203 | $47K |
| OP254 | <1% | 10,479 | $46K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 816 | $46K |
| 97164 | <1% | 1,012 | $46K | |
| 93041 | <1% | 3,511 | $44K | |
| 96401 | <1% | 921 | $44K | |
| 72050 | <1% | 780 | $43K | |
| 77412 | <1% | 344 | $43K | |
| 10005 | <1% | 95 | $43K | |
| 19081 | <1% | 58 | $43K | |
| 92523 | <1% | 657 | $42K | |
| 95806 | <1% | 53 | $41K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 182 | $41K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 1,055 | $40K |
| 0004A | <1% | 1,343 | $40K | |
| 94727 | <1% | 1,375 | $40K | |
| 88307 | <1% | 1,117 | $40K | |
| 84703 | <1% | 23,227 | $39K | |
| 85730 | <1% | 14,696 | $39K | |
| 84439 | <1% | 7,356 | $39K | |
| 81002 | <1% | 9,108 | $38K | |
| 75574 | <1% | 167 | $38K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,697 | $37K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,828 | $36K |
| 88304 | <1% | 2,107 | $35K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 144 | $35K |
| 29515 | <1% | 838 | $34K | |
| 84153 | <1% | 2,690 | $34K | |
| 87581 | <1% | 3,508 | $33K | |
| 86901 | <1% | 9,014 | $32K | |
| 72141 | <1% | 168 | $32K | |
| 95957 | <1% | 133 | $32K | |
| 87040 | <1% | 9,401 | $32K | |
| 73110 | <1% | 1,307 | $31K | |
| 87486 | <1% | 2,954 | $31K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,765 | $30K |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 29 | $29K |
| 73564 | <1% | 1,274 | $29K | |
| 85652 | <1% | 8,352 | $29K | |
| 82746 | <1% | 4,118 | $28K | |
| 77062 | <1% | 1,202 | $27K | |
| 83550 | <1% | 6,530 | $27K | |
| 0031A | <1% | 861 | $27K | |
| 10022 | <1% | 45 | $26K | |
| 74018 | <1% | 1,560 | $26K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,818 | $25K |
| 86300 | <1% | 3,410 | $25K | |
| C1874 | Stent, coated/covered, with delivery system | <1% | 37 | $25K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 751 | $24K |
| 83615 | <1% | 3,772 | $24K | |
| 83690 | <1% | 13,396 | $24K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,723 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,371 | $23K |
| 83605 | <1% | 7,177 | $22K | |
| 97035 | <1% | 1,324 | $22K | |
| 81003 | <1% | 13,904 | $22K | |
| 93325 | <1% | 124 | $22K | |
| 73502 | <1% | 1,314 | $22K | |
| 83540 | <1% | 6,652 | $21K | |
| 87077 | <1% | 4,839 | $21K | |
| 85007 | <1% | 7,043 | $20K | |
| 29125 | <1% | 470 | $20K | |
| C2615 | Sealant, pulmonary, liquid | <1% | 803 | $20K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 520 | $20K |
| 84480 | <1% | 2,774 | $20K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 72 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,374 | $19K |
| 87186 | <1% | 3,690 | $19K | |
| 97163 | <1% | 506 | $17K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $16K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 4,421 | $16K |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 15 | $16K |
| A4649 | Surgical supply; miscellaneous | <1% | 2,872 | $16K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,011 | $15K |
| 30802 | <1% | 26 | $15K | |
| 97018 | <1% | 2,048 | $15K | |
| 84702 | <1% | 2,724 | $15K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,596 | $15K |
| 76825 | <1% | 62 | $14K | |
| 94761 | <1% | 678 | $14K | |
| 82553 | <1% | 3,512 | $14K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 87 | $13K |
| 82784 | <1% | 1,784 | $13K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 623 | $13K |
| 85379 | <1% | 4,916 | $12K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,879 | $12K |
| 86140 | <1% | 6,282 | $12K | |
| 86301 | <1% | 431 | $11K | |
| 88341 | <1% | 712 | $11K | |
| 76827 | <1% | 61 | $11K | |
| 29505 | <1% | 311 | $11K | |
| 0072A | <1% | 307 | $10K | |
| 90714 | <1% | 1,394 | $10K | |
| 88173 | <1% | 213 | $10K | |
| C1729 | Catheter, drainage | <1% | 1,995 | $10K |
| 82150 | <1% | 3,756 | $10K | |
| 0071A | <1% | 305 | $9K | |
| 86769 | <1% | 394 | $9K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,634 | $9K |
| 76821 | <1% | 63 | $9K | |
| 93350 | <1% | 13 | $9K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 36 | $8K |
| 87071 | <1% | 3,137 | $8K | |
| 12001 | <1% | 146 | $8K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,857 | $8K |
| 36591 | <1% | 1,612 | $8K | |
| 73080 | <1% | 328 | $8K | |
| 77061 | <1% | 539 | $7K | |
| 95819 | <1% | 41 | $7K | |
| 86038 | <1% | 1,419 | $7K | |
| C1781 | Mesh (implantable) | <1% | 57 | $7K |
| 84550 | <1% | 2,387 | $7K | |
| 70486 | <1% | 101 | $7K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 347 | $7K |
| 82248 | <1% | 1,007 | $7K | |
| 74019 | <1% | 301 | $7K | |
| 96416 | <1% | 19 | $7K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 114 | $6K |
| 97533 | <1% | 184 | $6K | |
| 86304 | <1% | 604 | $6K | |
| 88360 | <1% | 235 | $6K | |
| 86039 | <1% | 659 | $6K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,289 | $6K |
| E1637 | Hemostats, each | <1% | 1,296 | $5K |
| 0064A | <1% | 198 | $5K | |
| 84145 | <1% | 1,068 | $5K | |
| 84403 | <1% | 460 | $5K | |
| 0124A | <1% | 250 | $5K | |
| 82043 | <1% | 2,301 | $5K | |
| 73590 | <1% | 273 | $5K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 19 | $5K |
| 76942 | <1% | 69 | $5K | |
| 84100 | <1% | 2,945 | $5K | |
| 86334 | <1% | 663 | $5K | |
| 80299 | <1% | 838 | $5K | |
| 82550 | <1% | 2,559 | $4K | |
| 77290 | <1% | 13 | $4K | |
| 86235 | <1% | 484 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 302 | $4K |
| 96368 | <1% | 190 | $4K | |
| 76870 | <1% | 38 | $4K | |
| 82565 | <1% | 1,015 | $4K | |
| 85045 | <1% | 1,378 | $4K | |
| 73221 | <1% | 15 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,115 | $4K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 301 | $4K |
| 77280 | <1% | 27 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,381 | $3K |
| 86430 | <1% | 1,046 | $3K | |
| 96521 | <1% | 27 | $3K | |
| 84520 | <1% | 805 | $3K | |
| 87205 | <1% | 1,385 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 101 | $3K |
| 95861 | <1% | 15 | $3K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 196 | $3K |
| 36430 | <1% | 33 | $3K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 329 | $3K |
| 78306 | <1% | 39 | $3K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 321 | $3K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 301 | $2K |
| 70491 | <1% | 14 | $2K | |
| 71101 | <1% | 67 | $2K | |
| 72072 | <1% | 136 | $2K | |
| 82985 | <1% | 859 | $2K | |
| 87340 | <1% | 381 | $2K | |
| 86225 | <1% | 539 | $2K | |
| 87081 | <1% | 1,023 | $2K | |
| 84165 | <1% | 708 | $2K | |
| 82803 | <1% | 260 | $2K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 74 | $2K |
| 82009 | <1% | 121 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,370 | $2K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 123 | $1K |
| 84154 | <1% | 160 | $1K | |
| 10060 | <1% | 16 | $1K | |
| 86706 | <1% | 263 | $1K | |
| 83090 | <1% | 103 | $1K | |
| 86920 | <1% | 62 | $1K | |
| 12011 | <1% | 12 | $1K | |
| 95813 | <1% | 15 | $1K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 16 | $1K |
| 84156 | <1% | 331 | $1K | |
| 83921 | <1% | 190 | $1K | |
| 29130 | <1% | 27 | $1K | |
| 83883 | <1% | 405 | $1K | |
| 86592 | <1% | 386 | $1K | |
| 80076 | <1% | 338 | $1K | |
| 86803 | <1% | 112 | $1K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 44 | $1K |
| 70490 | <1% | 19 | $1K | |
| 97168 | <1% | 25 | $999.14 | |
| 36600 | <1% | 192 | $989.64 | |
| 73090 | <1% | 58 | $929.84 | |
| 0134A | <1% | 59 | $900.31 | |
| 0012A | <1% | 44 | $867.15 | |
| 0011A | <1% | 55 | $836.73 | |
| 73140 | <1% | 83 | $832.56 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 1,074 | $800.63 |
| 82272 | <1% | 207 | $762.79 | |
| 87420 | <1% | 146 | $703.35 | |
| 84402 | <1% | 57 | $697.78 | |
| 86308 | <1% | 632 | $637.26 | |
| 0003A | <1% | 18 | $592.88 | |
| 77001 | <1% | 13 | $588.78 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 351 | $586.09 |
| OP270 | <1% | 599 | $582.23 | |
| 82164 | <1% | 114 | $581.48 | |
| 88302 | <1% | 40 | $556.86 | |
| 92610 | <1% | 29 | $549.27 | |
| 86787 | <1% | 48 | $532.63 | |
| 86360 | <1% | 34 | $510.59 | |
| 72170 | <1% | 38 | $497.17 | |
| 83516 | <1% | 123 | $464.63 | |
| 72131 | <1% | 13 | $408.89 | |
| 86357 | <1% | 33 | $384.50 | |
| 36416 | <1% | 532 | $382.67 | |
| 86355 | <1% | 33 | $379.86 | |
| 86800 | <1% | 55 | $366.56 | |
| 86359 | <1% | 33 | $366.34 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 25 | $362.60 |
| 84132 | <1% | 572 | $360.69 | |
| OP278 | <1% | 27 | $356.69 | |
| 88112 | <1% | 27 | $356.05 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 3,319 | $349.07 |
| 84481 | <1% | 44 | $333.57 | |
| 88172 | <1% | 37 | $325.71 | |
| 86063 | <1% | 100 | $248.11 | |
| 86762 | <1% | 43 | $239.31 | |
| 88142 | <1% | 13 | $234.00 | |
| 90686 | <1% | 83 | $233.35 | |
| 93356 | <1% | 20 | $207.45 | |
| 83020 | <1% | 51 | $205.38 | |
| 82085 | <1% | 101 | $189.04 | |
| 83520 | <1% | 54 | $187.39 | |
| 86704 | <1% | 43 | $182.76 | |
| 86376 | <1% | 12 | $179.83 | |
| 84270 | <1% | 27 | $155.24 | |
| 84436 | <1% | 103 | $130.33 | |
| M0201 | Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s) are performed at the patient's home | <1% | 75 | $112.27 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 43 | $94.21 |
| 82105 | <1% | 12 | $77.92 | |
| 82668 | <1% | 12 | $70.77 | |
| 87070 | <1% | 15 | $61.66 | |
| 82950 | <1% | 12 | $49.09 | |
| 80178 | <1% | 13 | $43.26 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 33 | $38.48 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 17 | $24.83 |
| 0077U | <1% | 15 | $20.23 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 12 | $14.15 |
| 82570 | <1% | 17 | $9.18 | |
| A4628 | Oral and/or oropharyngeal suction catheter, each | <1% | 12 | $3.00 |
| C1758 | Catheter, ureteral | <1% | 19 | $3.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZEHNER, DOUG (CFO)
| Provider | Location | Paid |
|---|---|---|
| Holy Name Medical Center INC | Teaneck, NJ | $412K |
| Holy Name Medical Center INC. | Teaneck, NJ | $91K |
| Holy Name Medical Center INC | Teaneck, NJ | $41K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.